Hyperfine, Inc. (HYPR) News
Follow Hyperfine, Inc. (HYPR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Hyperfine Q3 Revenue Rises on Higher System Sales; Net Loss Narrows
EQUITY | Nov 09, 2026, 09:21 PM UTC
M
Hyperfine Reports Third-Quarter 2026 Financial Results
Hyperfine announced its third-quarter 2026 financial results and provided a business update.
EQUITY | Nov 09, 2026, 09:05 PM UTC
H
Full Transcript: Hyperfine Q2 2026 Earnings Call
Hyperfine (NASDAQ: HYPR ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensive fin
LIVE | Oct 12, 2026, 09:24 AM UTC
H
Hyperfine shares are trading lower after the company reported its preliminary Q3 financial results and affirmed its FY26 sales guidance with its midpoint above estimates.
Hyperfine shares are trading lower after the company reported its preliminary Q3 financial results and affirmed its FY26 sales guidance with its midpoint above estimates.
LIVE | Oct 08, 2026, 01:02 PM UTC
H
Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est
Hyperfine (NASDAQ: HYPR ) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
LIVE | Oct 08, 2026, 11:38 AM UTC
M
Hyperfine posts preliminary Q3 revenue around $6.0 million
Hyperfine, Inc. (NASDAQ:HYPR) announced preliminary, unaudited Q3 revenue of about $6.0 million and reaffirmed its full-year 2026 revenue outlook of roughly $20 to $22 million.
EQUITY | Oct 08, 2026, 11:30 AM UTC
L
Hyperfine, Inc. (HYPR) Names Exclusive Distributor for Kuwait and UAE
Hyperfine appointed Roots Pharmaceutical as exclusive distributor for its Swoop portable brain MRI in Kuwait and the UAE, covering market development, regulatory support, and, post-clearances, commercialization and servi
NEWS | Sep 28, 2026, 12:15 PM UTC
L
Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the a
REGULATION | Sep 28, 2026, 12:15 PM UTC
L
Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that
REGULATION | Sep 15, 2026, 12:15 PM UTC
L
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
EQUITY | Aug 26, 2026, 12:20 PM UTC
L
Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est
Hyperfine (NASDAQ: HYPR ) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
EARNINGS | Aug 06, 2026, 08:16 PM UTC
M
Hyperfine Releases Peer-Reviewed Publications
Hyperfine expands clinical evidence for Swoop System
EQUITY | Jul 30, 2026, 12:16 PM UTC
L
HYPR Forms Advisory Council
HYPR Hyperfine forms global neurosurgery advisory council to support portable MRI expansion
EQUITY | Jun 22, 2026, 12:17 PM UTC